Merrell Pharmaceuticals, Inc.

Hoechst Marion Roussel

Sanofi

Aventis Pharmaceuticals Inc.

Merrell Dow Pharmaceuticals

Tieu-Binh Le

Timothy Paul Burkholder

Elizabeth M Kudlacz

George D Maynard

Brian S Freed

Martin Smrcina

Brian L Pedgrift

Stanly John

Gerard Charles Rosse

David Squire Thorpe

Antonio Daniel Ramos

Thomas Joseph Caulfield

William Shelly Wire

Jennifer Williford Clemens

Jianhong Zhao

Robert S Francis

The present invention relates to novel compounds of the formula Ia: in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity, and are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, Crohn's Disease, associated with the modulation of the human CXCR5 receptor.

Substituted benzoylamino-indan-2-carboxylic acids and related compounds

Substituted 4-(1H-benzimidazol-2-yl)&lsqb;1,4&rsqb;diazepanes useful for the treatment of allergic diseases

The present invention relates to substituted piperazinone derivatives of formula (1) or stereoisomers, or pharmaceutically acceptable salts thereof and their use as tachykinin receptor antagonists. Such antagonists are useful in the treatment of tachykinin-mediated diseases and conditions disclosed herein including: asthma, cough, and bronchitis. The present invention also relates to intermediates useful in the preparation of compounds of formula (1).

Heterocyclic substituted piperazinone derivatives

The present invention relates to substituted pyrrolidinyl-3-yl-alkyl-piperidines, their stereoisomers, and pharmaceutically acceptable salts thereof and processes for preparation of the same. The compounds of the present invention are useful in their pharmacological activities such as tachykinin antagonism, especially substance P and neurokinin A antagonism, and the like. Compounds having the property of tachykinin antagonism are indicated for conditions associated with neurogenic inflammation and other diseases described herein.

Substituted pyrrolidin-3-yl-alkyl-piperidines

The present invention relates to substituted piperazinone derivatives (compounds of formula (1)) or stereoisomers, or pharmaceutically acceptable salts thereof and their use as tachykinin receptor antagonists. Such antagonists are useful in the treatment of tachykinin-mediated diseases and conditions disclosed herein including: asthma, cough, and bronchitis. The present invention also relates to intermediates useful in the preparation of compounds of formula (1).

The present invention relates to substituted piperazine derivatives (herein referred to as compounds or compounds of formula (1)) or stereoisomers, or pharmaceutically acceptable salts thereof and their use as tachykinin receptor antagonists. Such antagonists are useful in the treatment of tachykinin-mediated diseases and conditions disclosed herein including: asthma, cough, and bronchitis.

Substituted piperazine derivatives

The present invention relates to novel substituted alkyldiamine derivatives and pharmaceutically acceptable salts thereof which are useful tachykinin antagonists. Such antagonists are useful in the treatment of tachykinin-mediated diseases and conditions including asthma, cough, and bronchitis.

Substituted alkyldiamine derivatives

Growing community of inventors

Cincinnati, OH, United States of America

Tieu-Binh Le